Plan B Backlash Blocks FDA Commissioner Nomination: Take Two
This article was originally published in The Tan Sheet
Executive Summary
FDA will not have a permanent commissioner until an actual decision is announced on the proposed Rx to-OTC switch of emergency contraceptive Plan B, if a hold by Senate Democrats is respected
You may also be interested in...
Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application
Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application
Plan B Draws Criticism During Von Eschenbach Confirmation Hearing
FDA's recent request to meet with Barr Labs about the proposed OTC sale of Plan B has done little to quell criticisms from Senate Democrats concerning the agency's extensive delays in issuing a decision on the Rx-to-OTC switch application